Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group
- 1 August 1994
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 70 (2) , 380-383
- https://doi.org/10.1038/bjc.1994.310
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.Journal of Clinical Oncology, 1993
- Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.1991
- Relationships between the structure of taxol analogs and their antimitotic activityJournal of Medicinal Chemistry, 1991
- EAP in advanced gastric cancer.Journal of Clinical Oncology, 1990
- 5-Fluorouracil, Doxorubicin (Adriamycin) and Mitomycin-C (FAM) in Advanced Gastric Cancer: Observations on Response, Patient Characteristics, Myelosuppression and Delivered DosageOncology, 1989
- Chemotherapy of gastric cancer: a review.1988
- An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.Journal of Clinical Oncology, 1986
- Cancer Statistics, 1985CA: A Cancer Journal for Clinicians, 1985
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980